Taxol is active in platinum-resistant endometrial adenocarcinoma.
Taxol, 170 mg/m2 by 3-h infusion every 3 weeks, was administered to seven patients with primarily advanced or recurrent endometrial cancer with progressive disease on platinum analogues. By standard response criteria, there were three clinical responders (43%; 95% confidence limits, 6-80%) and one disease stabilization. All three responses were clinical partial responses. The response duration ranged from 3 to 7 months. These preliminary results suggest that taxol is active in patients with platinum-resistant endometrial adenocarcinoma.
Woo
H L
HL
Department of Gynecologic Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Swenerton
K D
KD
Hoskins
P J
PJ
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use*; D004351:Drug Resistance; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*
D017239:Paclitaxel; D002945:Cisplatin